|
Market Closed -
Australian S.E.
19:17:34 2026-10-21 EDT
|
5-day change | 1st Jan Change | ||
| 0.0550 AUD | +10.00% |
|
+10.00% | -40.86% |
| 10-07 | Noxopharm Says US FDA Feedback Supports Planned Phase II Trial Approach for Autoimmune Drug Candidate | MT |
| 09-29 | Noxopharm Limited Auditor Raises 'Going Concern' Doubt | CI |
| Market Cap | 16.9M 11.88M 10.61M 9.8M 8.89M 16.62M 1.13B 118M 46.71M 591M 44.6M 43.65M 1.86B | P/E 2025 |
-3.23x | P/E 2026 | -5.8x |
|---|---|---|---|---|---|
| Enterprise Value | 21.18M 14.9M 13.3M 12.29M 11.14M 20.83M 1.41B 148M 58.54M 741M 55.9M 54.71M 2.34B | EV / Sales 2025 |
5.92x | EV / Sales 2026 | 21.7x |
| Free-Float |
68.25% | Yield 2025 * |
-
| Yield 2026 | - |
| 1 day | +10.00% | ||
| 1 week | +10.00% | ||
| Current month | -6.78% | ||
| 1 month | -9.84% | ||
| 3 months | -36.05% | ||
| 6 months | -16.67% | ||
| Current year | -40.86% |
| 1 week | 0.05 |  | 0.06 |
| 1 month | 0.05 | | 0.06 |
| Current year | 0.05 | | 0.11 |
| 1 year | 0.05 | | 0.11 |
| 3 years | 0.04 | | 0.15 |
| 5 years | 0.03 | | 0.57 |
| 10 years | 0.03 | | 1.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
Olivier Laczka
CEO | Chief Executive Officer | - | 2026-04-14 |
| Director of Finance/CFO | - | 2019-02-28 | |
Lara Babich
PRN | Corporate Officer/Principal | - | 2017-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Peter Marks
CHM | Chairman | 70 | 2016-03-14 |
Boris Patkin
BRD | Director/Board Member | - | 2020-03-25 |
Fred Bart Bart
CHM | Chairman | 71 | 2020-09-08 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/20/23 | Buy | Chairman | 880 | 0.0003% | ||
| 9/17/23 | Buy | Chairman | 253,001 | 0.0866% | ||
| 7/3/23 | Buy | Chairman | 135,281 | 0.0463% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +10.00% | +10.00% | -44.44% | -47.62% | 11.86M | |
| +2.41% | -6.33% | +43.43% | +71.02% | 63.29B | |
| -0.15% | +7.50% | +11.01% | +73.48% | 54.89B | |
| +0.57% | +4.60% | +10.07% | +92.86% | 53.28B | |
| +0.13% | +4.39% | +26.70% | +51.67% | 45.81B | |
| -1.32% | +2.18% | +21.64% | +123.50% | 43.46B | |
| -0.26% | +5.59% | +251.61% | +923.70% | 40.23B | |
| +0.05% | +6.75% | +14.48% | +56.75% | 33.45B | |
| +1.19% | -5.84% | +27.86% | -0.65% | 23.7B | |
| -0.38% | +5.68% | +36.43% | +27.54% | 23.76B | |
| Average | +1.22% | +1.29% | +39.88% | +137.22% | 38.19B | |
| Weighted average by Cap. | +0.35% | +0.55% | +47.62% | +159.49% |
| 2025 | 2026 | |
|---|---|---|
| Net sales | 2.82M 1.98M 1.77M 1.64M 1.48M 2.77M 188M 19.7M 7.8M 98.68M 7.45M 7.29M 311M | 1.43M 1M 897K 828K 751K 1.4M 95.3M 9.97M 3.95M 49.93M 3.77M 3.69M 157M |
| Net income | -4.88M -3.44M -3.07M -2.83M -2.57M -4.8M -326M -34.1M -13.5M -171M -12.89M -12.62M -539M | -4.46M -3.13M -2.8M -2.59M -2.34M -4.38M -298M -31.11M -12.32M -156M -11.76M -11.51M -491M |
| Net Debt | 925K 651K 581K 537K 486K 910K 61.76M 6.46M 2.56M 32.36M 2.44M 2.39M 102M | 4.28M 3.01M 2.69M 2.48M 2.25M 4.21M 286M 29.88M 11.83M 150M 11.3M 11.06M 472M |
Employees
-
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-22 | A$0.0550 | +10.00% | 119,918 |
| 26-10-21 | A$0.0500 | 0.00% | 4,800 |
| 26-10-20 | A$0.0500 | 0.00% | 35,104 |
| 26-10-19 | A$0.0500 | 0.00% | 43,164 |
| 26-10-16 | A$0.0500 | 0.00% | 418,216 |
- Stock Market
- Stocks
- NOX Stock
Select your edition
All financial news and data tailored to specific country editions
